Clene Inc. (CLNN) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Clene Inc. (CLNN) has a cash flow conversion efficiency ratio of 0.241x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-4.53 Million) by net assets ($-18.81 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Clene Inc. liquidity coverage in days to measure how many days the company can operate on defensive assets alone.
Clene Inc. - Cash Flow Conversion Efficiency Trend (2018–2025)
This chart illustrates how Clene Inc.'s cash flow conversion efficiency has evolved over time, based on yearly financial data.
Clene Inc. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Clene Inc. ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
SBI Investment KOREA Co. Ltd
KQ:019550
|
-0.020x |
|
CKM Building Material
TWO:8930
|
0.054x |
|
DaChan Food (Asia) Limited
F:3DS
|
N/A |
|
Titijaya Land Bhd
KLSE:5239
|
0.048x |
|
ESTec Corporation
KQ:069510
|
0.036x |
|
Metro Systems Corporation Public Company Limited
BK:MSC
|
0.239x |
|
Roo Hsing Co Ltd
TW:4414
|
0.060x |
|
Surf Air Mobility Inc.
NYSE:SRFM
|
0.209x |
Annual Cash Flow Conversion Efficiency for Clene Inc. (2018–2025)
The table below shows the annual cash flow conversion efficiency of Clene Inc. from 2018 to 2025. For the full company profile with market capitalisation and key ratios, see CLNN market cap overview.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $-17.59 Million | $-18.55 Million | 1.054x | -56.22% |
| 2024-12-31 | $-8.86 Million | $-21.33 Million | 2.408x | +206.86% |
| 2023-12-31 | $13.39 Million | $-30.17 Million | -2.253x | +81.30% |
| 2022-12-31 | $3.24 Million | $-39.01 Million | -12.052x | -338.46% |
| 2021-12-31 | $12.60 Million | $-34.62 Million | -2.749x | +95.05% |
| 2020-12-31 | $341.00K | $-18.93 Million | -55.510x | -1955.61% |
| 2019-12-31 | $4.89 Million | $-13.20 Million | -2.700x | -6474.48% |
| 2018-12-31 | $5.00 Million | $-205.37K | -0.041x | -- |
About Clene Inc.
Clene Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. The company's lead drug candidate is CNM-Au8, which is being studied in various clinical trials, including a completed Phase 2 platform trial to evaluate the safety and efficacy of CNM-Au8 in patients with amyotrophic lateral … Read more